[go: up one dir, main page]

WO2000040273A8 - Treatment of viral diseases using an interferon omega expressing polynucleotide - Google Patents

Treatment of viral diseases using an interferon omega expressing polynucleotide

Info

Publication number
WO2000040273A8
WO2000040273A8 PCT/US1999/030843 US9930843W WO0040273A8 WO 2000040273 A8 WO2000040273 A8 WO 2000040273A8 US 9930843 W US9930843 W US 9930843W WO 0040273 A8 WO0040273 A8 WO 0040273A8
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
viral diseases
interferon omega
expressing polynucleotide
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/030843
Other languages
French (fr)
Other versions
WO2000040273A2 (en
WO2000040273A3 (en
Inventor
Suezanne Parker
Holly Horton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Tracks Therapeutics Inc
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Publication of WO2000040273A2 publication Critical patent/WO2000040273A2/en
Publication of WO2000040273A3 publication Critical patent/WO2000040273A3/en
Publication of WO2000040273A8 publication Critical patent/WO2000040273A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a method of treating a viral disease comprising administering to a mammal a polynucleotide construct comprising a polynucleotide encoding IFNφ. The polynucleotide construct of the present invention can be administered free from associated with transfection facilitating agents or as a complex with at least one or more cationic lipids.
PCT/US1999/030843 1999-01-08 1999-12-28 Treatment of viral diseases using an interferon omega expressing polynucleotide Ceased WO2000040273A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11540399P 1999-01-08 1999-01-08
US60/115,403 1999-01-08

Publications (3)

Publication Number Publication Date
WO2000040273A2 WO2000040273A2 (en) 2000-07-13
WO2000040273A3 WO2000040273A3 (en) 2000-11-16
WO2000040273A8 true WO2000040273A8 (en) 2001-01-11

Family

ID=22361168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030843 Ceased WO2000040273A2 (en) 1999-01-08 1999-12-28 Treatment of viral diseases using an interferon omega expressing polynucleotide

Country Status (1)

Country Link
WO (1) WO2000040273A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001080897A2 (en) 2000-04-21 2001-11-01 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
AU2587002A (en) 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
CA2466228A1 (en) * 2001-11-09 2003-08-07 Biomedicines, Inc. Method for treating diseases with omega interferon
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
NZ593017A (en) 2006-08-09 2011-08-26 Intarcia Therapeutics Inc Piston assembly for positioning lumen in an osmotic delivery system having groove to retain elastomeric O-ring
RU2440097C2 (en) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Method of treating insulin-independent diabetes and obesity, osmotic delivery system and method for making it
SMT201700583T1 (en) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2013095755A (en) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd Cationic lipid
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (en) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド Implant installation and removal system
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (en) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド A method comprising continuous administration of a GLP-1 receptor agonist and co-administration of drugs
JP2023545009A (en) * 2020-10-02 2023-10-26 イムノン、インコーポレイテッド Polynucleotide vaccines and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67786T1 (en) * 1984-08-01 1991-10-15 Boehringer Ingelheim Int NEW GENETIC SEQUENCES ENCODED BY TYPE I INTERFERON PEPTIDES AND THEIR PRODUCING ORGANISMS.
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
WO2000040273A2 (en) 2000-07-13
WO2000040273A3 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
WO2000040273A8 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
AU7295601A (en) Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO1996010419A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
WO1999003508A3 (en) METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
EP1758998A4 (en) Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
WO1999002143A3 (en) Medicament comprising adenosine
WO2001029175A3 (en) Antisense modulation of fra-1 expression
EP1133997A3 (en) Treatment of immune diseases with beta-interferon
IL142581A (en) Medicament for treating heart disease
WO1999021538A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
AU5155700A (en) Gene therapy of pulmonary disease
WO2000043028A3 (en) Method of treating chronic cardiac disease
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
WO2001014415A3 (en) Egfh2 genes and gene products
AU2002364757A8 (en) Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
WO2001094570A3 (en) Transfection method
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
WO2003066806A3 (en) Therapeutic use of aziridino compounds
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
WO2001075021A3 (en) A novel polypeptide, glucose transport-associated human protein 10 and the polynucleotide encoding the polypeptide
WO2002038188A3 (en) Use of the human lrp/mvp promotor for a vector that can be induced by therapy
WO2001068693A8 (en) A novel polypeptide, human cannabinoid receptor protein 7 and the polynucleotide encoding thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WR Later publication of a revised version of an international search report
122 Ep: pct application non-entry in european phase